Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588758 | 0.80 | ALDH1A1 (0.57) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL522853 | 0.73 | POLB (0.54) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14876599 | 0.72 | POLB (0.57) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14876105 | 0.71 | ALDH1A1 (0.62) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL524126 | 0.69 | ALDH1A1 (0.67) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL30522630 | 0.69 | ALDH1A1 (0.55) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL1177477 | 0.69 | ALDH1A1 (0.55) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL1989875 | 0.69 | ALDH1A1 (0.61) | MEN1KMT2ARAB9APOLBMAPT | |
| SCHEMBL11453214 | 0.66 | HPGD (0.55) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL25583424 | 0.66 | POLB (0.81) | MEN1KMT2APOLBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-7098211-B2 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1554267-A1 | DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY | Artesian Therapeutics, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040242648-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004033444-A1 | DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY | ARTESIAN THERAPEUTICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242648-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | CACNA1C, PDE3A, PDE3B | MEN1 1325/4885KMT2A 3592/4885NPC1 2200/4885 |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | CACNA1C, PDE3A, PDE3B | MEN1 1325/4885KMT2A 3592/4885NPC1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.